SNYR - Synergy CHC Total Debt to Capital

Public company logo of Synergy CHC Corp. (SNYR)

This chart of the total debt-to-equity ratio for Synergy CHC Corp (SNYR) reflects 0.00. This results from rising traffic acquisition costs in the DTC segment and declining customer loyalty. The business relies on developing niche wellness brands through web promotion, while outsourcing operational processes and logistics to third-party contractors to concentrate on identifying promising assets.

SNYR: Synergy CHC Corporation Total Debt to Capital 10/24/2024 - 10/03/2026
Core merchandise of Synergy CHC

For Synergy CHC Corp (SNYR), changes in the total debt-to-equity ratio reflect the balance between debt financing and equity, determining the holding's level of dependence on creditors. This metric measures total liabilities per unit of equity, allowing for an assessment of the extent to which investments in biotechnological R&D and retail digitalization rely on external loans, which is critical for the business's resilience to macroeconomic shocks.

Competitor analysis for Synergy CHC Corp

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|PRGO - Debt to Equity|All Debt to Shareholders' Equity Ratio ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Debt to Equity|Total Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital mannkindcorp.com|Total Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - All Debt to Shareholders' Equity Ratio|Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Debt to Capital|AQST: Total Debt to Equity Ratio|scPharmaceuticals Inc. - Aggregate Debt to Capital|TECX: Total Debt to Capital|Tonix Pharma - All Debt to Shareholders' Equity Ratio|SXTC (SXT Pharmaceuticals) - Total Debt to Capital|Debt to Capital Eupraxia Pharma EPRX|Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Oramed Pharmaceuticals Inc. ORMP|Total Debt to Capital Coefficient Entera Bio Ltd (ENTX)|HYFT: Total Debt to Equity Ratio|Debt to Capital ABVC BioPharma, Inc|Cumberland Pharmaceuticals (CPIX) - Debt to Equity|Debt to Equity Ratio QNTM|FGEN (FibroGen) - Total Debt to Capital|Debt to Capital Telomir Pharmaceuticals Inc TELO|Debt to Equity Rani Therapeutics (RANI)|RLYB (rallybio.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|Debt to Capital Ratio pulmatrix.com|PTHL: Total Debt to Equity Ratio|Debt to Capital Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc) - Total Debt to Equity Ratio|Impact BioMedical, Inc. - All Debt to Shareholders' Equity Ratio|TNFA (TNF Pharmaceuticals Inc.) - Total Debt to Capital|Total Debt to Equity Ratio cbdMD Corp (YCBD)|Total Debt to Capital PRFX|CYTO (altamiratherapeutics.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LIPO (Lipella)|OPTN - Total Debt to Equity Ratio|PIRS: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio PROC (procapsgroup.com)|PTPI: Total Debt to Capital|Total Debt to Equity Ratio Qilian International Holding Group|Debt to Equity ACELYRIN, Inc.|Debt to Capital TFF Pharmaceuticals, Inc TFFP